What does Terns Pharma do?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to discovering and developing an innovative portfolio of small-molecule product candidates targeting serious oncological diseases and metabolic conditions. The company's clinical pipeline includes advanced therapies such as an allosteric BCR-ABL tyrosine kinase inhibitor designed for chronic myeloid leukemia, alongside oral small-molecule treatments targeting obesity and metabolic disorders. By leveraging precision molecular engineering, Terns aims to deliver transformative therapeutic options for patients with high unmet medical needs.
Related FAQs
Yes, Pacific Western Bank and Banc of California completed a transformational merger on December 1, 2023.
Terns Pharmaceuticals, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Market under the ticker symbol TERN on February 5, 2021.
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. was officially founded in 2016 by a team of seasoned biopharmaceutical executives and life science entrepreneurs.
Merck KGaA (the prominent German science and technology enterprise) expanded its specialty pharmaceutical and bioprocessing pipeline by completing the strategic acquisition of SpringWorks Therapeutics, a commercial-stage biopharmaceutical company foc...
Merck & Co. is an entirely independent, publicly traded American multinational pharmaceutical corporation listed on the New York Stock Exchange and is not owned by Bayer.
Terns Pharmaceuticals, Inc.
Terumo Corporation operates with a massive global workforce of approximately thirty thousand five hundred ninety-one consolidated associates, functioning as a world-leading medical technology company.
Investing in pharmaceutical equities offers defensive characteristics, steady cash flows, and exposure to breakthrough medical innovations such as oncology treatments and metabolic disease therapies.
Terns Pharmaceuticals, trading under the ticker symbol TERN, is a clinical-stage biopharmaceutical enterprise focused on developing treatments for oncology and chronic disease conditions.
Merck entered into a definitive agreement to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion.
Tern PLC (AIM: TERN), an investment company specializing in the Internet of Things (IoT) technology sector, maintains a public market capitalization valuation fluctuating around 10.6 million British Pounds (roughly 1.
Financial analysts covering Terns Pharmaceuticals, Inc. (NASDAQ: TERN) maintain consensus 12-month average price targets that underscore the high-growth, high-risk profile characteristic of clinical-stage biopharmaceutical enterprises.
Tern plc, traded on the London Stock Exchange under the ticker TERN, belongs to the Technology sector.